(Q50044080)

http://europepmc.org/abstract/MED/28922160

24 February 2018

meta-analysis

0 references

title

Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. (English)

1 reference

http://europepmc.org/abstract/MED/28922160

24 February 2018

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nakao Iwata

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Taro Kishi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Shinji Matsunaga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Kazuto Oya

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ikuo Nomura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

11 September 2017

1 reference

http://europepmc.org/abstract/MED/28922160

24 February 2018

published in

Journal of Alzheimer's Disease

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

401-425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Pharmacologic treatment of apathy in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of Held synapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Development and validation of a geriatric depression screening scale: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Clinical evaluation of global change in Alzheimer's disease: identifying consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Nicotinic receptors in the brain. Links between molecular biology and behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

Memantine agonist action at dopamine D2High receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-170424

21 January 2018

Identifiers

DOI

10.3233/JAD-170424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28922160%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference